StreetInsider.com  2 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+Reports+Dosing+in+Novartis+%28NVS%29+Phase+12+Using+Bilateral+Hearing+Loss+Treatment+Tech/9951089.html for the full story.
newratings.com  Oct 28  Comment 
BRUSSELS (dpa-AFX) - Swiss stocks emerged from recent slumber on Tuesday, rising sharply following strong earnings reports from UBS and Novartis. The Swiss Market Index rose 1.29 percent, and is outperforming other European markets by rising more...
FiercePharma  Oct 28  Comment 
Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot...
FierceBiotech  Oct 28  Comment 
Novartis' pharma chief has hailed the company's forthcoming heart failure treatment as "the most exciting launch the company has ever had," and now the drugmaker's CEO has declared a "multi-blockbuster" in the making, joining a chorus of analysts...
MarketWatch  Oct 28  Comment 
Novartis rises after posting a 44% jump in profits.
Benzinga  Oct 28  Comment 
Novartis AG (NYSE: NVS) reported a rise in its third-quarter profit. The company's net profit attributable to shareholders climbed 44% to $3.22 billion, versus a year-ago profit of $2.23 billion. Its earnings, excluding some items, rose 9% to...
Reuters  Oct 28  Comment 
* Shares up 2.2 percent (Adds details, CEO quote, shares)
Wall Street Journal  Oct 28  Comment 
Novartis said a pretax gain from the sale of its stake in a U.S. drug company and continued productivity improvement pushed third-quarter earnings 44% higher.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki